Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Feb. 20, 2018. Ricki Chase.

Executive Summary

Lachman Consultant Services' Ricki Chase sees too many companies falling down on design control activities when they set out to make combination device/drug products. Check out what she said here.

"Design control is going to be required for a combination product. And it's hard to go back and do a retrospective design history file, because you've not captured a lot of the information that you need to do those things, such as design verification and design validation, along the way. And the fact is, if you're not caught [with inadequate design control] on submission of [your US FDA pre-market] application, you will be caught at the [FDA] pre-approval inspection when they ask to review your design control, or in post-market, when they come to do a post-market approval inspection, or a routine inspection, and they ask you about your design control." –Ricki Chase, compliance practice director, Lachman Consultant Services

  • Find out more: Compliance 360° Part 13: Navigating The Quicksand Of Device/Drug Combo Products (2 of 2)

Click here for a free trial of Medtech Insight

Advertisement

Related Content

Compliance 360° Part 13: Navigating The Quicksand Of Device/Drug Combo Products (2 of 2)
Compliance 360° Part 12: Navigating The Quicksand Of Device/Drug Combo Products (1 of 2)

Topics

Advertisement
UsernamePublicRestriction

Register

MT122214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel